Craig Rayner

---

Craig Rayner FRCP (Edin) is an Australian scientist that holds a Professorship in Pharmaceutical Science (Monash University, Australia), is employed at Certara (a New Jersey, USA, based company), and has published over 110 peer-reviewed research studies.

In December 2022, Rayner was announced as Director, Regional Centre for Respiratory Medicines and Tropical Disease for Moderna. This Regional Centre is associated with Moderna's first mRNA production facility in the Southern Hemisphere, which is projected to produce up to 100 million vaccine doses each year

Rayner was a senior investigator on the TOGETHER TRIAL, which was named "The David Sackett Trial of the Year (2021)". As a part of this trial, he was corresponding author on the paper, "Effect of Early Treatment with Ivermectin among Patients with Covid-19" published in New England Journal of Medicine. In regards to this paper, Rayner said, "We found that treatment with ivermectin did not reduce the need for medical admissions to hospital settings for COVID-19 patients... We examined it from multiple angles, multiple sub-group analyses, and ultimately, there is no suggestion of important clinical efficacy from ivermectin on COVID-19."

In 2017, Rayner led an analysis and report on Australian national security issues and recommended that Australia increase it's pandemic preparedness. "Dr Rayner's report, commissioned by the Department of Defence's Science and Technology agency, analysed Australia's ability to develop "medical countermeasures" – vaccines and drugs – for threats including pandemics, radiation and chemical and bioweapons."

He sits on the World Health Organization's therapeutics committee for COVID-19.

Rayner was President of Integrated Drug Development with Certara Strategic Consulting. Prior to that role, Rayner was the co-founder and CEO of drug development consulting firm d3 Medicine until its acquisition by Certara in 2016.

Research

Rayner has worked in early and late development of therapeutics and regulatory experience with all major global health authority. He has over 110 peer-reviewed publications.

TOGETHER Trail

Rayner is a co-investigator on the TOGETHER trial. The TOGETHER trial looked at 11 potential therapies for COVID-19, including hydroxychloroquine and ivermectin. The researches found two drugs had efficacy against COVID-19 symptoms – fluvoxamine and pegylated interferon. However, the most discussed outcome of this trial was the demonstration that Ivermectin showed no medical benefit.

Ivermectin

Initially, Ivermectin was not intended to be a part of the TOGETHER trial because Rayner had modelled the effective drug doses and the ivermectin dose required to kill the virus was more than 20 times the maximum dose approved for other purposes. Therefore, Rayner initially advised against Ivermectin's inclusion in the trial. However, by mid 2020, ivermectin had increased in notoriety as a possible, although unsubstantiated, COVID 'cure'. Due to this increased notoriety of Ivermectin, the TOGETHER trial authors decided to include it in the study and as reported by Rayner, "we had an obligation" and "we realised the answer was unknown."

The resulting research demonstrated that Ivermection showed no medical benefit.

Media Presence

Rayner has been mentioned and/or quoted in the following articles from news outlets:

• "What are COVID antivirals and who can have them?"

• "The Ivermectin Guys’ Whole Thing Has Really Fallen Apart"
• "How a false science ‘cure’ became Australia’s contribution to the pandemic"
• "Major study confirms ivermectin useless against COVID-19"
• "Pauline Hanson Sends Message To Aussies Who Want Her To Drop Dead After Testing Positive For Covid-19"
• "Major Study Finds Ivermectin Has No Medical Benefit Against Covid-19"
• "How an Australian COVID cure conquered the world - despite no robust evidence it works"
• "Why older, cheaper drugs that could treat COVID never leave the lab"

Work history

Rayner was President of Integrated Drug Development with Certara Strategic Consulting. Prior to that role, Rayner was the co-founder and CEO of drug development consulting firm d3 Medicine until its acquisition by Certara in 2016.

Craig's other appointments have included leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche), and in clinical pharmacology and infectious disease research (Monash University).

Education

Rayner received his bachelor's degrees in pharmacy and pharmaceutical science from Monash University, his doctor of pharmacy from State University of New York at Buffalo, and his MBA from Melbourne University.

Awards

Senior investigator on the TOGETHER TRIAL which was named "The David Sackett Trial of the Year (2021)"

Recipient of 2018 Distinguished Alumni Award for Monash University. President and Vice-Chancellor Professor Margaret Gardner AO told Rayner that he was selected to receive the award in 'recognition of your integrity and ability to inspire others to strive for excellence, your exceptional contribution to your professional field, your community leadership and your ability to inspire our students to reach their highest potential.'

Rayner was inducted as a fellow of the Royal College of Physicians of Edinburgh in Scotland.

References

This article "Craig Rayner" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Craig Rayner. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Magsud Gurbanov
• Kostruba Anatoliy
• Robert Bury Ferguson
• RBM Partnership to End Malaria
• Damir Filipovic
• Stephen Neidle
• Giuliana Galli Carminati

---